Moustafa A. Mansour
Moustafa A. Mansour has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Hamdi Nabawi Mostafa
Department of Neurosurgery Nasser Institute for Research and Treatment Cairo Egypt
19 shared publicationsMohamed Abdel-Fattah El-Salamoni
Department of Human Physiology and Basic Medical Sciences, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
9 shared publicationsAhmad A. Ayad
From the Department of Neurology and Neurologic Surgery (M.A.M., A.A.A.), Faculty of Medicine, Al-Azhar University, Cairo, Egypt; Department of Neurology and Neurologic Surgery (M.A.M.), Mayo Clinic, Rochester, MN; Division of Neuro-Intensive Care (M.A.M.), Dar Al-Fouad Medical Corporation; Department of Emergency Medicine and Critical Care (M.A.M., A.A.A.); Department of Pediatrics (H.A.); and Division of Neurology and Neurodevelopmental Disorders (H.A.), Department of Pediatrics, Faculty of...
7 shared publicationsMohamed H. Helmy
6 shared publicationsTaha Mohammed Adel
6 shared publicationsDyana F. Khalil
Department of Oncology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
5 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Elsevier in World Neurosurgery: X
- Vol. 32
Peritumoral edema and imaging markers of aggressiveness in intracranial meningiomas: A combined predictive model
- 23 September 2026
- Published by Elsevier in World Neurosurgery: X
- Vol. 32
Open AccessPeritumoral edema and imaging markers of aggressiveness in intracranial meningiomas: A combined predictive model
- Open Access
- 14 September 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 49, 101438
The parasitic synapse: How gliomas hijack the connectome for malignant gain
- 14 September 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 49, 101438
Open AccessThe parasitic synapse: How gliomas hijack the connectome for malignant gain
- Open Access
Central Nervous System Aspergillosis: Advances in Diagnosis, Therapeutics, and Multidisciplinary Management (2026 Update)
Background: Central nervous system (CNS) aspergillosis is a life‐threatening infection with mortality rates exceeding 50%, especially in immunocompromised patients. Significant challenges persist due to limited antifungal drug penetration into the CNS, emerging resistance, and diagnostic delays, despite advancements in therapy and diagnostics. Objective: This comprehensive review aims to synthesize pivotal advances in the management of CNS aspergillosis from 2020 to 2026 and to provide a multidisciplinary framework for addressing these ongoing challenges. Methods: We conducted a comprehensive evaluation of the latest clinical data, pharmacokinetic studies, and expert recommendations from the specified period. The review critically appraises evidence on pharmacological therapies, diagnostic technologies, and adjunctive treatment strategies. Findings: Key findings include: Pharmacotherapy : Voriconazole remains the cornerstone of therapy due to its superior CNS penetration (CSF:Plasma ratio ~50%). The roles of alternatives like isavuconazole, salvage combination regimens, and novel agents (e.g., olorofim, fosmanogepix) are evolving. Diagnostics : Cutting‐edge tools such as AI‐assisted imaging, metagenomic next‐generation sequencing (mNGS), and MR spectroscopy for trehalose detection show significant potential for enabling earlier and more accurate diagnosis. Adjunctive Strategies : Neurosurgical intervention, immunomodulation, and therapeutic drug monitoring (TDM) are critical for optimizing outcomes. Emerging strategies like nanoparticle‐based drug delivery and host‐directed therapies (e.g., PD‐1/PD‐L1 blockade) offer promising avenues to overcome the blood–brain barrier. Conclusion: This review integrates the latest evidence to provide a timely and actionable resource for clinicians. It bridges gaps in existing guidelines by offering a multidisciplinary approach that addresses the complex management of CNS aspergillosis, with particular relevance for high‐risk populations such as COVID‐19 and immunocompromised patients.
Open AccessCentral Nervous System Aspergillosis: Advances in Diagnosis, Therapeutics, and Multidisciplinary Management (2026 Update)
Background: Central nervous system (CNS) aspergillosis is a life‐threatening infection with mortality rates exceeding 50%, especially in immunocompromised patients. Significant challenges persist due to limited antifungal drug penetration into the CNS, emerging resistance, and diagnostic delays, despite advancements in therapy and diagnostics. Objective: This comprehensive review aims to synthesize pivotal advances in the management of CNS aspergillosis from 2020 to 2026 and to provide a multidisciplinary framework for addressing these ongoing challenges. Methods: We conducted a comprehensive evaluation of the latest clinical data, pharmacokinetic studies, and expert recommendations from the specified period. The review critically appraises evidence on pharmacological therapies, diagnostic technologies, and adjunctive treatment strategies. Findings: Key findings include: Pharmacotherapy : Voriconazole remains the cornerstone of therapy due to its superior CNS penetration (CSF:Plasma ratio ~50%). The roles of alternatives like isavuconazole, salvage combination regimens, and novel agents (e.g., olorofim, fosmanogepix) are evolving. Diagnostics : Cutting‐edge tools such as AI‐assisted imaging, metagenomic next‐generation sequencing (mNGS), and MR spectroscopy for trehalose detection show significant potential for enabling earlier and more accurate diagnosis. Adjunctive Strategies : Neurosurgical intervention, immunomodulation, and therapeutic drug monitoring (TDM) are critical for optimizing outcomes. Emerging strategies like nanoparticle‐based drug delivery and host‐directed therapies (e.g., PD‐1/PD‐L1 blockade) offer promising avenues to overcome the blood–brain barrier. Conclusion: This review integrates the latest evidence to provide a timely and actionable resource for clinicians. It bridges gaps in existing guidelines by offering a multidisciplinary approach that addresses the complex management of CNS aspergillosis, with particular relevance for high‐risk populations such as COVID‐19 and immunocompromised patients.
- Open Access
- 17 August 2026
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 74
Cerebral cryptococcoma masquerading as high-grade glioma in an immunocompetent traveler from South America: A diagnostic challenge and systematic review
- 17 August 2026
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 74
Open AccessCerebral cryptococcoma masquerading as high-grade glioma in an immunocompetent traveler from South America: A diagnostic challenge and systematic review
- Open Access
- 1 August 2026
- Published by Elsevier in Radiology Case Reports
- Vol. 21 (10) , 5076-5082
A rare case of primary intracranial myxoma in a 10-year-old male: Case report and literature review
- 1 August 2026
- Published by Elsevier in Radiology Case Reports
- Vol. 21 (10) , 5076-5082
Open AccessA rare case of primary intracranial myxoma in a 10-year-old male: Case report and literature review
- Open Access
- 11 June 2026
- Published by Elsevier in Neuroimage: Reports
- Vol. 6 (3) , 100369
The damaged connectome: Mechanisms and consequences of brain network reorganization following neurotrauma
- 11 June 2026
- Published by Elsevier in Neuroimage: Reports
- Vol. 6 (3) , 100369
Open AccessThe damaged connectome: Mechanisms and consequences of brain network reorganization following neurotrauma
- Open Access
- 25 May 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 11 (21)
When one becomes many: a pediatric case of extensive multilevel spinal extradural arachnoid cysts challenging diagnostic paradigms. Illustrative case
BACKGROUND: Spinal extradural arachnoid cysts (SEACs) are rare, typically solitary lesions. Multilevel SEACs are exceptionally uncommon. This report highlights a pediatric case of extensive thoracic SEACs, emphasizing their potential for rapid neurological decline and the importance of early recognition in atypical spinal cord compression. OBSERVATIONS: A 13-year-old female presented with progressive myelopathy due to multilevel SEACs (C7–L2), challenging the notion of SEACs as usually solitary. Imaging revealed severe cord compression (flattened to < 2 mm at T4–7). Surgical intervention (laminotomy, cyst excision, dural repair) led to significant recovery. Histopathological analysis confirmed the diagnosis, demonstrating hypocellular fibrous cyst walls without neoplastic or inflammatory features, supporting a developmental origin and differentiating SEACs from mimics. This case expands the understanding of SEACs as potentially extensive, high-risk lesions in children. LESSONS: This case underscores the need to consider SEACs in pediatric progressive myelopathy, even with atypical symptoms. Histopathological confirmation is critical to exclude mimics and guide management. Rapidly progressive decline necessitates timely surgery when cord compression is evident. Successful surgical outcomes set a precedent for complex SEACs. The rarity of multilevel SEACs raises questions about underlying connective tissue or genetic predispositions. This report advances the literature on multifocal SEACs and refines diagnostic and management approaches. https://thejns.org/doi/10.3171/CASE25312
- 25 May 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 11 (21)
Open AccessWhen one becomes many: a pediatric case of extensive multilevel spinal extradural arachnoid cysts challenging diagnostic paradigms. Illustrative case
BACKGROUND: Spinal extradural arachnoid cysts (SEACs) are rare, typically solitary lesions. Multilevel SEACs are exceptionally uncommon. This report highlights a pediatric case of extensive thoracic SEACs, emphasizing their potential for rapid neurological decline and the importance of early recognition in atypical spinal cord compression. OBSERVATIONS: A 13-year-old female presented with progressive myelopathy due to multilevel SEACs (C7–L2), challenging the notion of SEACs as usually solitary. Imaging revealed severe cord compression (flattened to < 2 mm at T4–7). Surgical intervention (laminotomy, cyst excision, dural repair) led to significant recovery. Histopathological analysis confirmed the diagnosis, demonstrating hypocellular fibrous cyst walls without neoplastic or inflammatory features, supporting a developmental origin and differentiating SEACs from mimics. This case expands the understanding of SEACs as potentially extensive, high-risk lesions in children. LESSONS: This case underscores the need to consider SEACs in pediatric progressive myelopathy, even with atypical symptoms. Histopathological confirmation is critical to exclude mimics and guide management. Rapidly progressive decline necessitates timely surgery when cord compression is evident. Successful surgical outcomes set a precedent for complex SEACs. The rarity of multilevel SEACs raises questions about underlying connective tissue or genetic predispositions. This report advances the literature on multifocal SEACs and refines diagnostic and management approaches. https://thejns.org/doi/10.3171/CASE25312
- Open Access
- 14 February 2026
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 70, 102959
Cerebral schistosomiasis masquerading as a CNS malignancy in a sudanese traveler: A diagnostic challenge and review of literature
- 14 February 2026
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 70, 102959
Open AccessCerebral schistosomiasis masquerading as a CNS malignancy in a sudanese traveler: A diagnostic challenge and review of literature
- Open Access
- 8 January 2026
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 7 (1)
A Clinicoradiological Series of 39 Gangliogliomas: Insights into Surgical Outcomes and Prognostic Factors
BACKGROUND AND OBJECTIVES: Gangliogliomas (GGs) are rare, well-differentiated glioneuronal tumors, representing a common cause of neoplastic epilepsy. This study analyzes the presentation, management, and outcomes of a large single-center cohort. METHODS: We retrospectively reviewed 39 patients with histologically confirmed GG. Data on demographics, clinical presentation, imaging, surgical management, and follow-up were analyzed. RESULTS: The mean patient age was 20.8 years. The most common presenting symptom was epilepsy (94.9%, 37/39), with complex partial seizures being predominant. Tumors were predominantly temporal (46.2%, 18/39), followed by cerebellar (15.4%, 6/39) and parietal (12.8%, 5/39) locations. A solid-cystic morphology was the most common radiological pattern (51.3%, 20/39). Gross total resection (GTR) was achieved in 71.8% (28/39) of cases. At a mean follow-up of 7.2 years, 86.5% (32/37) of patients with preoperative epilepsy were seizure-free (Engel Class I). Seizure freedom was significantly associated with GTR ( P < .001). Recurrence/progression was observed in 7 patients (17.9%), strongly associated with anaplastic histology ( P < .001), and subtotal resection ( P = .003). The overall prognosis was excellent for classic GG, with a 100% 10-year survival rate for low-grade tumors. CONCLUSION: GGs have a favorable prognosis after GTR, with excellent rates of seizure control. Tumor recurrence, though rare, is linked to high-grade features and incomplete resection. This series underscores the importance of maximal safe resection as the primary treatment.
- 8 January 2026
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 7 (1)
Open AccessA Clinicoradiological Series of 39 Gangliogliomas: Insights into Surgical Outcomes and Prognostic Factors
BACKGROUND AND OBJECTIVES: Gangliogliomas (GGs) are rare, well-differentiated glioneuronal tumors, representing a common cause of neoplastic epilepsy. This study analyzes the presentation, management, and outcomes of a large single-center cohort. METHODS: We retrospectively reviewed 39 patients with histologically confirmed GG. Data on demographics, clinical presentation, imaging, surgical management, and follow-up were analyzed. RESULTS: The mean patient age was 20.8 years. The most common presenting symptom was epilepsy (94.9%, 37/39), with complex partial seizures being predominant. Tumors were predominantly temporal (46.2%, 18/39), followed by cerebellar (15.4%, 6/39) and parietal (12.8%, 5/39) locations. A solid-cystic morphology was the most common radiological pattern (51.3%, 20/39). Gross total resection (GTR) was achieved in 71.8% (28/39) of cases. At a mean follow-up of 7.2 years, 86.5% (32/37) of patients with preoperative epilepsy were seizure-free (Engel Class I). Seizure freedom was significantly associated with GTR ( P < .001). Recurrence/progression was observed in 7 patients (17.9%), strongly associated with anaplastic histology ( P < .001), and subtotal resection ( P = .003). The overall prognosis was excellent for classic GG, with a 100% 10-year survival rate for low-grade tumors. CONCLUSION: GGs have a favorable prognosis after GTR, with excellent rates of seizure control. Tumor recurrence, though rare, is linked to high-grade features and incomplete resection. This series underscores the importance of maximal safe resection as the primary treatment.
- Open Access
- 29 November 2025
- Published by Elsevier in World Neurosurgery
- Vol. 205, 124695
Decoding Meningioangiomatosis: A Century of Insights into Molecular Mechanisms, Clinical Dilemmas, and Therapeutic Innovations
- 29 November 2025
- Published by Elsevier in World Neurosurgery
- Vol. 205, 124695
Open AccessDecoding Meningioangiomatosis: A Century of Insights into Molecular Mechanisms, Clinical Dilemmas, and Therapeutic Innovations